Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-03-29

AUTHORS

Romain Guilhaumou, Sihem Benaboud, Youssef Bennis, Claire Dahyot-Fizelier, Eric Dailly, Peggy Gandia, Sylvain Goutelle, Sandrine Lefeuvre, Nicolas Mongardon, Claire Roger, Julien Scala-Bertola, Florian Lemaitre, Marc Garnier

ABSTRACT

BackgroundBeta-lactam antibiotics (βLA) are the most commonly used antibiotics in the intensive care unit (ICU). ICU patients present many pathophysiological features that cause pharmacokinetic (PK) and pharmacodynamic (PD) specificities, leading to the risk of underdosage. The French Society of Pharmacology and Therapeutics (SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (SFAR) have joined forces to provide guidelines on the optimization of beta-lactam treatment in ICU patients.MethodsA consensus committee of 18 experts from the two societies had the mission of producing these guidelines. The entire process was conducted independently of any industry funding. A list of questions formulated according to the PICO model (Population, Intervention, Comparison, and Outcomes) was drawn-up by the experts. Then, two bibliographic experts analysed the literature published since January 2000 using predefined keywords according to PRISMA recommendations. The quality of the data identified from the literature was assessed using the GRADE® methodology. Due to the lack of powerful studies having used mortality as main judgement criteria, it was decided, before drafting the recommendations, to formulate only “optional” recommendations.ResultsAfter two rounds of rating and one amendment, a strong agreement was reached by the SFPT-SFAR guideline panel for 21 optional recommendations and a recapitulative algorithm for care covering four areas: (i) pharmacokinetic variability, (ii) PK-PD relationship, (iii) administration modalities, and (iv) therapeutic drug monitoring (TDM). The most important recommendations regarding βLA administration in ICU patients concerned (i) the consideration of the many sources of PK variability in this population; (ii) the definition of free plasma concentration between four and eight times the Minimal Inhibitory Concentration (MIC) of the causative bacteria for 100% of the dosing interval as PK-PD target to maximize bacteriological and clinical responses; (iii) the use of continuous or prolonged administration of βLA in the most severe patients, in case of high MIC bacteria and in case of lower respiratory tract infection to improve clinical cure; and (iv) the use of TDM to improve PK-PD target achievement.ConclusionsThe experts strongly suggest the use of personalized dosing, continuous or prolonged infusion and therapeutic drug monitoring when administering βLA in critically ill patients. More... »

PAGES

104

References to SciGraph publications

  • 2016-06-22. Evaluation of an alternative extended-infusion piperacillin–tazobactam dosing strategy for the treatment of gram-negative infections in INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
  • 2012-11-13. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia in CRITICAL CARE
  • 2011-06-22. Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials in BMC INFECTIOUS DISEASES
  • 2011-09-13. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams in CRITICAL CARE
  • 2016-04-04. Piperacillin concentration in relation to therapeutic range in critically ill patients – a prospective observational study in CRITICAL CARE
  • 2015-12-30. Renal replacement therapy in adult and pediatric intensive care in ANNALS OF INTENSIVE CARE
  • 1996-05. Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient in INTENSIVE CARE MEDICINE
  • 2012-11-13. The Clinical Relevance of Plasma Protein Binding Changes in CLINICAL PHARMACOKINETICS
  • 2000-11. Pharmacokinetics and Pharmacodynamics of Cephalosporins in Cerebrospinal Fluid in CLINICAL PHARMACOKINETICS
  • 2008-03. Population Pharmacokinetics of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy in CLINICAL PHARMACOKINETICS
  • 2011-06-06. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy in CRITICAL CARE
  • 2017-07-28. Neurological Adverse Effects Attributable to β-Lactam Antibiotics: A Literature Review in DRUG SAFETY
  • 2013-12-20. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial in INTENSIVE CARE MEDICINE
  • 2013-05-01. Obesity-related physiological changes and their pharmacokinetic consequences in JOURNAL OF PHARMACEUTICAL INVESTIGATION
  • 2013-02-28. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients in CRITICAL CARE
  • 2011-02. The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients in CLINICAL PHARMACOKINETICS
  • 2010-04-01. Prospective monitoring of cefepime in intensive care unit adult patients in CRITICAL CARE
  • 2010-01. Augmented Renal Clearance in CLINICAL PHARMACOKINETICS
  • 2016-01-11. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis in INTENSIVE CARE MEDICINE
  • 2017-10-12. Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis in EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
  • 2013-11-07. Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy in CRITICAL CARE
  • 2010-05. Kinetics of Imipenem Distribution into the Peritoneal Fluid of Patients with Severe Peritonitis Studied by Microdialysis in CLINICAL PHARMACOKINETICS
  • 2002-03-22. Changes in plasma protein binding have little clinical relevance in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2018-09-24. Pharmacokinetics–pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients in CRITICAL CARE
  • 2017-11-14. Cefepime-induced neurotoxicity: a systematic review in CRITICAL CARE
  • 2016-11-04. High target attainment for β-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied in EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
  • 2010-07-01. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock in CRITICAL CARE
  • 2012-07-28. Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review in ANNALS OF INTENSIVE CARE
  • Journal

    TITLE

    Critical Care

    ISSUE

    1

    VOLUME

    23

    Author Affiliations

  • AP-HM Hôpital de la Timone, Service de Pharmacologie Clinique et Pharmacovigilance, 264 rue Saint Pierre, 13005, Marseille, France
  • AP-HP Hôpital Cochin, Service de Pharmacologie, 27 rue du Faubourg St-Jacques, 75679, Paris Cedex 14, France
  • CHU d’Amiens Picardie, Service de Pharmacologie Clinique, UPJV EA7517, Avenue Laennec, 80054, Amiens Cedex 1, France
  • CHU de Poitiers, Département d’Anesthésie Réanimation, 2 Rue de la Milétrie, 86021, Poitiers, France
  • CHU de Nantes, Département de Pharmacologie Clinique, 5 allée de l’île gloriette, 44093, Nantes Cedex 01, France
  • CHU de Toulouse, Laboratoire de Pharmacocinétique et Toxicologie Clinique, Institut Fédératif de Biologie, 330, avenue de Grande-Bretagne, 31059, Toulouse cedex 9, France
  • CHU de Lyon, Service de Pharmacie, Groupement Hospitalier Nord, Hôpital Pierre Garraud, 136 rue du Commandant Charcot, 69322, Lyon cedex 05, France
  • CHR d’Orléans, Laboratoire de Biochimie, 14 Avenue de l’Hôpital, 45067, Orléans, France
  • AP-HP Hôpital Henri Mondor, Département d’Anesthésie-Réanimation, 51 Avenue du Maréchal de Lattre de Tassigny, 94000, Créteil, France
  • CHU de Nîmes, Département d’anesthésie, réanimation, douleur et médicine d’urgence, Place du Pr Robert Debré, 30029, Nîmes cedex 9, France
  • CHRU de Nancy, Département de pharmacologie clinique et de toxicologie, 29 rue Lionnois, 54000, Nancy, France
  • CHU Pontchaillou, Service de Pharmacologie Clinique et épidémiologique, 2 Rue Henri le Guilloux, 35000, Rennes, France
  • AP-HP Hôpital Tenon, Département d’Anesthésie et Réanimation, 4 rue de la Chine, 75020, Paris, France
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s13054-019-2378-9

    DOI

    http://dx.doi.org/10.1186/s13054-019-2378-9

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1113107158

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/30925922


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Anti-Bacterial Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Critical Illness", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Dosage Calculations", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Monitoring", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "France", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Glomerular Filtration Rate", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Guidelines as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Intensive Care Units", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Serum Albumin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Societies, Medical", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Societies, Pharmaceutical", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "beta-Lactamases", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "AP-HM H\u00f4pital de la Timone, Service de Pharmacologie Clinique et Pharmacovigilance, 264 rue Saint Pierre, 13005, Marseille, France", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "AP-HM H\u00f4pital de la Timone, Service de Pharmacologie Clinique et Pharmacovigilance, 264 rue Saint Pierre, 13005, Marseille, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Guilhaumou", 
            "givenName": "Romain", 
            "id": "sg:person.01205666273.30", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205666273.30"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "AP-HP H\u00f4pital Cochin, Service de Pharmacologie, 27 rue du Faubourg St-Jacques, 75679, Paris Cedex 14, France", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "AP-HP H\u00f4pital Cochin, Service de Pharmacologie, 27 rue du Faubourg St-Jacques, 75679, Paris Cedex 14, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Benaboud", 
            "givenName": "Sihem", 
            "id": "sg:person.01032325745.23", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032325745.23"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "CHU d\u2019Amiens Picardie, Service de Pharmacologie Clinique, UPJV EA7517, Avenue Laennec, 80054, Amiens Cedex 1, France", 
              "id": "http://www.grid.ac/institutes/grid.413858.3", 
              "name": [
                "CHU d\u2019Amiens Picardie, Service de Pharmacologie Clinique, UPJV EA7517, Avenue Laennec, 80054, Amiens Cedex 1, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bennis", 
            "givenName": "Youssef", 
            "id": "sg:person.01203524231.40", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203524231.40"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "CHU de Poitiers, D\u00e9partement d\u2019Anesth\u00e9sie R\u00e9animation, 2 Rue de la Mil\u00e9trie, 86021, Poitiers, France", 
              "id": "http://www.grid.ac/institutes/grid.411162.1", 
              "name": [
                "CHU de Poitiers, D\u00e9partement d\u2019Anesth\u00e9sie R\u00e9animation, 2 Rue de la Mil\u00e9trie, 86021, Poitiers, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dahyot-Fizelier", 
            "givenName": "Claire", 
            "id": "sg:person.01352406745.54", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352406745.54"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "CHU de Nantes, D\u00e9partement de Pharmacologie Clinique, 5 all\u00e9e de l\u2019\u00eele gloriette, 44093, Nantes Cedex 01, France", 
              "id": "http://www.grid.ac/institutes/grid.277151.7", 
              "name": [
                "CHU de Nantes, D\u00e9partement de Pharmacologie Clinique, 5 all\u00e9e de l\u2019\u00eele gloriette, 44093, Nantes Cedex 01, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dailly", 
            "givenName": "Eric", 
            "id": "sg:person.01065077071.65", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065077071.65"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "CHU de Toulouse, Laboratoire de Pharmacocin\u00e9tique et Toxicologie Clinique, Institut F\u00e9d\u00e9ratif de Biologie, 330, avenue de Grande-Bretagne, 31059, Toulouse cedex 9, France", 
              "id": "http://www.grid.ac/institutes/grid.411175.7", 
              "name": [
                "CHU de Toulouse, Laboratoire de Pharmacocin\u00e9tique et Toxicologie Clinique, Institut F\u00e9d\u00e9ratif de Biologie, 330, avenue de Grande-Bretagne, 31059, Toulouse cedex 9, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gandia", 
            "givenName": "Peggy", 
            "id": "sg:person.01311772632.70", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311772632.70"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "CHU de Lyon, Service de Pharmacie, Groupement Hospitalier Nord, H\u00f4pital Pierre Garraud, 136 rue du Commandant Charcot, 69322, Lyon cedex 05, France", 
              "id": "http://www.grid.ac/institutes/grid.413852.9", 
              "name": [
                "CHU de Lyon, Service de Pharmacie, Groupement Hospitalier Nord, H\u00f4pital Pierre Garraud, 136 rue du Commandant Charcot, 69322, Lyon cedex 05, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Goutelle", 
            "givenName": "Sylvain", 
            "id": "sg:person.01111665536.58", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111665536.58"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "CHR d\u2019Orl\u00e9ans, Laboratoire de Biochimie, 14 Avenue de l\u2019H\u00f4pital, 45067, Orl\u00e9ans, France", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "CHR d\u2019Orl\u00e9ans, Laboratoire de Biochimie, 14 Avenue de l\u2019H\u00f4pital, 45067, Orl\u00e9ans, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lefeuvre", 
            "givenName": "Sandrine", 
            "id": "sg:person.0664453716.41", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664453716.41"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "AP-HP H\u00f4pital Henri Mondor, D\u00e9partement d\u2019Anesth\u00e9sie-R\u00e9animation, 51 Avenue du Mar\u00e9chal de Lattre de Tassigny, 94000, Cr\u00e9teil, France", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "AP-HP H\u00f4pital Henri Mondor, D\u00e9partement d\u2019Anesth\u00e9sie-R\u00e9animation, 51 Avenue du Mar\u00e9chal de Lattre de Tassigny, 94000, Cr\u00e9teil, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Mongardon", 
            "givenName": "Nicolas", 
            "id": "sg:person.01216312122.58", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216312122.58"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "CHU de N\u00eemes, D\u00e9partement d\u2019anesth\u00e9sie, r\u00e9animation, douleur et m\u00e9dicine d\u2019urgence, Place du Pr Robert Debr\u00e9, 30029, N\u00eemes cedex 9, France", 
              "id": "http://www.grid.ac/institutes/grid.411165.6", 
              "name": [
                "CHU de N\u00eemes, D\u00e9partement d\u2019anesth\u00e9sie, r\u00e9animation, douleur et m\u00e9dicine d\u2019urgence, Place du Pr Robert Debr\u00e9, 30029, N\u00eemes cedex 9, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Roger", 
            "givenName": "Claire", 
            "id": "sg:person.0604417143.54", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0604417143.54"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "CHRU de Nancy, D\u00e9partement de pharmacologie clinique et de toxicologie, 29 rue Lionnois, 54000, Nancy, France", 
              "id": "http://www.grid.ac/institutes/grid.410527.5", 
              "name": [
                "CHRU de Nancy, D\u00e9partement de pharmacologie clinique et de toxicologie, 29 rue Lionnois, 54000, Nancy, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Scala-Bertola", 
            "givenName": "Julien", 
            "id": "sg:person.01302555643.53", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302555643.53"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "CHU Pontchaillou, Service de Pharmacologie Clinique et \u00e9pid\u00e9miologique, 2 Rue Henri le Guilloux, 35000, Rennes, France", 
              "id": "http://www.grid.ac/institutes/grid.414271.5", 
              "name": [
                "CHU Pontchaillou, Service de Pharmacologie Clinique et \u00e9pid\u00e9miologique, 2 Rue Henri le Guilloux, 35000, Rennes, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lemaitre", 
            "givenName": "Florian", 
            "id": "sg:person.01110354341.05", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110354341.05"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "AP-HP H\u00f4pital Tenon, D\u00e9partement d\u2019Anesth\u00e9sie et R\u00e9animation, 4 rue de la Chine, 75020, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.50550.35", 
              "name": [
                "AP-HP H\u00f4pital Tenon, D\u00e9partement d\u2019Anesth\u00e9sie et R\u00e9animation, 4 rue de la Chine, 75020, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Garnier", 
            "givenName": "Marc", 
            "id": "sg:person.07443737243.21", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07443737243.21"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1186/s13613-015-0093-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026015877", 
              "https://doi.org/10.1186/s13613-015-0093-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/11318140-000000000-00000", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039277611", 
              "https://doi.org/10.2165/11318140-000000000-00000"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s13318-017-0439-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1092187076", 
              "https://doi.org/10.1007/s13318-017-0439-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/11539220-000000000-00000", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045065825", 
              "https://doi.org/10.2165/11539220-000000000-00000"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00134-015-4188-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029454839", 
              "https://doi.org/10.1007/s00134-015-4188-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s40264-017-0578-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1090909191", 
              "https://doi.org/10.1007/s40264-017-0578-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10096-016-2832-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029650859", 
              "https://doi.org/10.1007/s10096-016-2832-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/cc9091", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031159164", 
              "https://doi.org/10.1186/cc9091"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/cc10257", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005923181", 
              "https://doi.org/10.1186/cc10257"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/cc8941", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040862782", 
              "https://doi.org/10.1186/cc8941"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s40262-012-0018-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026024203", 
              "https://doi.org/10.1007/s40262-012-0018-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13054-018-2155-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1107133834", 
              "https://doi.org/10.1186/s13054-018-2155-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1067/mcp.2002.121829", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044113659", 
              "https://doi.org/10.1067/mcp.2002.121829"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1471-2334-11-181", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017207082", 
              "https://doi.org/10.1186/1471-2334-11-181"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/cc10441", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037453353", 
              "https://doi.org/10.1186/cc10441"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13054-017-1856-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1092690158", 
              "https://doi.org/10.1186/s13054-017-1856-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003088-200847030-00003", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033831230", 
              "https://doi.org/10.2165/00003088-200847030-00003"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/cc12544", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1041305613", 
              "https://doi.org/10.1186/cc12544"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/cc13094", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023558979", 
              "https://doi.org/10.1186/cc13094"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003088-200039050-00003", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033874588", 
              "https://doi.org/10.2165/00003088-200039050-00003"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/cc11862", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017822371", 
              "https://doi.org/10.1186/cc11862"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01712162", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038871033", 
              "https://doi.org/10.1007/bf01712162"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00134-013-3187-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016715841", 
              "https://doi.org/10.1007/s00134-013-3187-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s40005-013-0073-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047074920", 
              "https://doi.org/10.1007/s40005-013-0073-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/2110-5820-2-35", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020507376", 
              "https://doi.org/10.1186/2110-5820-2-35"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11096-016-0334-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020337346", 
              "https://doi.org/10.1007/s11096-016-0334-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/11319370-000000000-00000", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045903643", 
              "https://doi.org/10.2165/11319370-000000000-00000"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13054-016-1255-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012708353", 
              "https://doi.org/10.1186/s13054-016-1255-z"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2019-03-29", 
        "datePublishedReg": "2019-03-29", 
        "description": "BackgroundBeta-lactam antibiotics (\u03b2LA) are the most commonly used antibiotics in the intensive care unit (ICU). ICU patients present many pathophysiological features that cause pharmacokinetic (PK) and pharmacodynamic (PD) specificities, leading to the risk of underdosage. The French Society of Pharmacology and Therapeutics (SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (SFAR) have joined forces to provide guidelines on the optimization of beta-lactam treatment in ICU patients.MethodsA consensus committee of 18 experts from the two societies had the mission of producing these guidelines. The entire process was conducted independently of any industry funding. A list of questions formulated according to the PICO model (Population, Intervention, Comparison, and Outcomes) was drawn-up by the experts. Then, two bibliographic experts analysed the literature published since January 2000 using predefined keywords according to PRISMA recommendations. The quality of the data identified from the literature was assessed using the GRADE\u00ae methodology. Due to the lack of powerful studies having used mortality as main judgement criteria, it was decided, before drafting the recommendations, to formulate only \u201coptional\u201d recommendations.ResultsAfter two rounds of rating and one amendment, a strong agreement was reached by the SFPT-SFAR guideline panel for 21 optional recommendations and a recapitulative algorithm for care covering four areas: (i) pharmacokinetic variability, (ii) PK-PD relationship, (iii) administration modalities, and (iv) therapeutic drug monitoring (TDM). The most important recommendations regarding \u03b2LA administration in ICU patients concerned (i) the consideration of the many sources of PK variability in this population; (ii) the definition of free plasma concentration between four and eight times the Minimal Inhibitory Concentration (MIC) of the causative bacteria for 100% of the dosing interval as PK-PD target to maximize bacteriological and clinical responses; (iii) the use of continuous or prolonged administration of \u03b2LA in the most severe patients, in case of high MIC bacteria and in case of lower respiratory tract infection to improve clinical cure; and (iv) the use of TDM to improve PK-PD target achievement.ConclusionsThe experts strongly suggest the use of personalized dosing, continuous or prolonged infusion and therapeutic drug monitoring when administering \u03b2LA in critically ill patients.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s13054-019-2378-9", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1117766", 
            "issn": [
              "1364-8535", 
              "1466-609X"
            ], 
            "name": "Critical Care", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "23"
          }
        ], 
        "keywords": [
          "therapeutic drug monitoring", 
          "intensive care unit", 
          "intensive care medicine", 
          "ICU patients", 
          "minimal inhibitory concentration", 
          "care medicine", 
          "use of TDM", 
          "drug monitoring", 
          "lower respiratory tract infections", 
          "PK-PD targets", 
          "respiratory tract infections", 
          "free plasma concentrations", 
          "PK-PD relationship", 
          "beta-lactam treatment", 
          "main judgment criterion", 
          "beta-lactam antibiotics", 
          "pharmacodynamic specificity", 
          "risk of underdosage", 
          "clinical cure", 
          "clinical response", 
          "tract infections", 
          "severe patients", 
          "ill patients", 
          "care unit", 
          "French Society", 
          "pathophysiological features", 
          "pharmacokinetic variability", 
          "guideline panel", 
          "prolonged administration", 
          "prolonged infusion", 
          "PK variability", 
          "plasma concentrations", 
          "causative bacteria", 
          "administration modalities", 
          "PICO model", 
          "PRISMA recommendations", 
          "patients", 
          "personalized dosing", 
          "consensus committee", 
          "ConclusionsThe experts", 
          "inhibitory concentration", 
          "anesthesia", 
          "optional recommendations", 
          "antibiotics", 
          "powerful studies", 
          "administration", 
          "pharmacology", 
          "target achievement", 
          "treatment", 
          "industry funding", 
          "therapeutics", 
          "two-round", 
          "medicine", 
          "guidelines", 
          "recommendations", 
          "infusion", 
          "dosing", 
          "mortality", 
          "infection", 
          "care", 
          "strong agreement", 
          "cure", 
          "underdosage", 
          "modalities", 
          "risk", 
          "cases", 
          "use", 
          "important recommendations", 
          "grade", 
          "population", 
          "concentration", 
          "bacteria", 
          "specificity", 
          "monitoring", 
          "response", 
          "interval", 
          "list of questions", 
          "target", 
          "literature", 
          "experts", 
          "Committee", 
          "criteria", 
          "judgment criteria", 
          "study", 
          "lack", 
          "variability", 
          "ratings", 
          "panel", 
          "keywords", 
          "rounds", 
          "society", 
          "data", 
          "quality", 
          "list", 
          "relationship", 
          "funding", 
          "units", 
          "time", 
          "features", 
          "area", 
          "definition", 
          "questions", 
          "consideration", 
          "model", 
          "source", 
          "entire process", 
          "achievement", 
          "process", 
          "force", 
          "agreement", 
          "methodology", 
          "optimization", 
          "amendments", 
          "mission", 
          "algorithm"
        ], 
        "name": "Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique\u2014SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation\u2014SFAR)", 
        "pagination": "104", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1113107158"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s13054-019-2378-9"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "30925922"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s13054-019-2378-9", 
          "https://app.dimensions.ai/details/publication/pub.1113107158"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-05-20T07:36", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_822.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s13054-019-2378-9"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13054-019-2378-9'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13054-019-2378-9'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13054-019-2378-9'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13054-019-2378-9'


     

    This table displays all metadata directly associated to this object as RDF triples.

    462 TRIPLES      22 PREDICATES      183 URIs      147 LITERALS      21 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s13054-019-2378-9 schema:about N3230b8208695463786db0da8ec9eebcf
    2 N4abf8eb04ae94fd4a98aca168bd79db9
    3 N4b2273feb3ef4b3b8cd7c3252a91b9f2
    4 N54dcbe71ed784a0daf11390401a555ad
    5 N8099d3a3a16f4da790d3e65f278ccaf8
    6 N8c715525617f4215910d124d4b7f0723
    7 N8f138b2e3ba6448ca0e8aa1d0749078a
    8 N95f3ac8a0a9149afa250444f3e31d284
    9 Nb09483f4c14e47439030cb571c28f328
    10 Nb8a4331bea3542ec8b29f7c1044ae46a
    11 Nccf0cdd1cb3649d4be42e34e79d902c5
    12 Nedf92b1e35024b32850ea81a1bb7a915
    13 Nf33967c5ae904eaca4b58e72a982b97b
    14 Nfc9b81b0fe5b49259d7b7bb3cf643b66
    15 anzsrc-for:11
    16 anzsrc-for:1103
    17 schema:author Nf9c0ce98a75b4194804bac1afb8b3edc
    18 schema:citation sg:pub.10.1007/bf01712162
    19 sg:pub.10.1007/s00134-013-3187-2
    20 sg:pub.10.1007/s00134-015-4188-0
    21 sg:pub.10.1007/s10096-016-2832-4
    22 sg:pub.10.1007/s11096-016-0334-1
    23 sg:pub.10.1007/s13318-017-0439-5
    24 sg:pub.10.1007/s40005-013-0073-4
    25 sg:pub.10.1007/s40262-012-0018-5
    26 sg:pub.10.1007/s40264-017-0578-2
    27 sg:pub.10.1067/mcp.2002.121829
    28 sg:pub.10.1186/1471-2334-11-181
    29 sg:pub.10.1186/2110-5820-2-35
    30 sg:pub.10.1186/cc10257
    31 sg:pub.10.1186/cc10441
    32 sg:pub.10.1186/cc11862
    33 sg:pub.10.1186/cc12544
    34 sg:pub.10.1186/cc13094
    35 sg:pub.10.1186/cc8941
    36 sg:pub.10.1186/cc9091
    37 sg:pub.10.1186/s13054-016-1255-z
    38 sg:pub.10.1186/s13054-017-1856-1
    39 sg:pub.10.1186/s13054-018-2155-1
    40 sg:pub.10.1186/s13613-015-0093-5
    41 sg:pub.10.2165/00003088-200039050-00003
    42 sg:pub.10.2165/00003088-200847030-00003
    43 sg:pub.10.2165/11318140-000000000-00000
    44 sg:pub.10.2165/11319370-000000000-00000
    45 sg:pub.10.2165/11539220-000000000-00000
    46 schema:datePublished 2019-03-29
    47 schema:datePublishedReg 2019-03-29
    48 schema:description BackgroundBeta-lactam antibiotics (βLA) are the most commonly used antibiotics in the intensive care unit (ICU). ICU patients present many pathophysiological features that cause pharmacokinetic (PK) and pharmacodynamic (PD) specificities, leading to the risk of underdosage. The French Society of Pharmacology and Therapeutics (SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (SFAR) have joined forces to provide guidelines on the optimization of beta-lactam treatment in ICU patients.MethodsA consensus committee of 18 experts from the two societies had the mission of producing these guidelines. The entire process was conducted independently of any industry funding. A list of questions formulated according to the PICO model (Population, Intervention, Comparison, and Outcomes) was drawn-up by the experts. Then, two bibliographic experts analysed the literature published since January 2000 using predefined keywords according to PRISMA recommendations. The quality of the data identified from the literature was assessed using the GRADE® methodology. Due to the lack of powerful studies having used mortality as main judgement criteria, it was decided, before drafting the recommendations, to formulate only “optional” recommendations.ResultsAfter two rounds of rating and one amendment, a strong agreement was reached by the SFPT-SFAR guideline panel for 21 optional recommendations and a recapitulative algorithm for care covering four areas: (i) pharmacokinetic variability, (ii) PK-PD relationship, (iii) administration modalities, and (iv) therapeutic drug monitoring (TDM). The most important recommendations regarding βLA administration in ICU patients concerned (i) the consideration of the many sources of PK variability in this population; (ii) the definition of free plasma concentration between four and eight times the Minimal Inhibitory Concentration (MIC) of the causative bacteria for 100% of the dosing interval as PK-PD target to maximize bacteriological and clinical responses; (iii) the use of continuous or prolonged administration of βLA in the most severe patients, in case of high MIC bacteria and in case of lower respiratory tract infection to improve clinical cure; and (iv) the use of TDM to improve PK-PD target achievement.ConclusionsThe experts strongly suggest the use of personalized dosing, continuous or prolonged infusion and therapeutic drug monitoring when administering βLA in critically ill patients.
    49 schema:genre article
    50 schema:inLanguage en
    51 schema:isAccessibleForFree true
    52 schema:isPartOf N7da6ff61c50742898f653c4191030406
    53 N8c920f83968445f1a744494abd18811f
    54 sg:journal.1117766
    55 schema:keywords Committee
    56 ConclusionsThe experts
    57 French Society
    58 ICU patients
    59 PICO model
    60 PK variability
    61 PK-PD relationship
    62 PK-PD targets
    63 PRISMA recommendations
    64 achievement
    65 administration
    66 administration modalities
    67 agreement
    68 algorithm
    69 amendments
    70 anesthesia
    71 antibiotics
    72 area
    73 bacteria
    74 beta-lactam antibiotics
    75 beta-lactam treatment
    76 care
    77 care medicine
    78 care unit
    79 cases
    80 causative bacteria
    81 clinical cure
    82 clinical response
    83 concentration
    84 consensus committee
    85 consideration
    86 criteria
    87 cure
    88 data
    89 definition
    90 dosing
    91 drug monitoring
    92 entire process
    93 experts
    94 features
    95 force
    96 free plasma concentrations
    97 funding
    98 grade
    99 guideline panel
    100 guidelines
    101 ill patients
    102 important recommendations
    103 industry funding
    104 infection
    105 infusion
    106 inhibitory concentration
    107 intensive care medicine
    108 intensive care unit
    109 interval
    110 judgment criteria
    111 keywords
    112 lack
    113 list
    114 list of questions
    115 literature
    116 lower respiratory tract infections
    117 main judgment criterion
    118 medicine
    119 methodology
    120 minimal inhibitory concentration
    121 mission
    122 modalities
    123 model
    124 monitoring
    125 mortality
    126 optimization
    127 optional recommendations
    128 panel
    129 pathophysiological features
    130 patients
    131 personalized dosing
    132 pharmacodynamic specificity
    133 pharmacokinetic variability
    134 pharmacology
    135 plasma concentrations
    136 population
    137 powerful studies
    138 process
    139 prolonged administration
    140 prolonged infusion
    141 quality
    142 questions
    143 ratings
    144 recommendations
    145 relationship
    146 respiratory tract infections
    147 response
    148 risk
    149 risk of underdosage
    150 rounds
    151 severe patients
    152 society
    153 source
    154 specificity
    155 strong agreement
    156 study
    157 target
    158 target achievement
    159 therapeutic drug monitoring
    160 therapeutics
    161 time
    162 tract infections
    163 treatment
    164 two-round
    165 underdosage
    166 units
    167 use
    168 use of TDM
    169 variability
    170 schema:name Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique—SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d’Anesthésie et Réanimation—SFAR)
    171 schema:pagination 104
    172 schema:productId N03e06a925cbc4a708d3ec15bd6a89e86
    173 N629e992e50b847a099174abb172910f8
    174 Nfc1a29b69d1544f2993ebf6f4bb66315
    175 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113107158
    176 https://doi.org/10.1186/s13054-019-2378-9
    177 schema:sdDatePublished 2022-05-20T07:36
    178 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    179 schema:sdPublisher N62199429b1f746ceb64f863902e2b80e
    180 schema:url https://doi.org/10.1186/s13054-019-2378-9
    181 sgo:license sg:explorer/license/
    182 sgo:sdDataset articles
    183 rdf:type schema:ScholarlyArticle
    184 N03e06a925cbc4a708d3ec15bd6a89e86 schema:name doi
    185 schema:value 10.1186/s13054-019-2378-9
    186 rdf:type schema:PropertyValue
    187 N15adfb29a0934c0ebf4d6e49104b6e4f rdf:first sg:person.01032325745.23
    188 rdf:rest Na1813939014748c2b4a744e78abcba14
    189 N20103e746350447a8acfaee286d404eb rdf:first sg:person.01302555643.53
    190 rdf:rest N6afc4e0587da45bd93dc80ba46d352f1
    191 N213b49fa706d43dba035b640441ba812 rdf:first sg:person.0604417143.54
    192 rdf:rest N20103e746350447a8acfaee286d404eb
    193 N21ab78da2e84461ca1fd1cd86aad44d7 rdf:first sg:person.01065077071.65
    194 rdf:rest Nb413b5e6e8ae41e58748a5a137a66046
    195 N3230b8208695463786db0da8ec9eebcf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    196 schema:name Drug Dosage Calculations
    197 rdf:type schema:DefinedTerm
    198 N4abf8eb04ae94fd4a98aca168bd79db9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    199 schema:name Critical Illness
    200 rdf:type schema:DefinedTerm
    201 N4b2273feb3ef4b3b8cd7c3252a91b9f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    202 schema:name Treatment Outcome
    203 rdf:type schema:DefinedTerm
    204 N4e777c2fe96b48dda6ab11d0a93cdb1d rdf:first sg:person.01111665536.58
    205 rdf:rest Nb191c15c5cbc4a8592a5abcd504d40f8
    206 N54c4b8508b3d4c21875a644771164e90 rdf:first sg:person.01216312122.58
    207 rdf:rest N213b49fa706d43dba035b640441ba812
    208 N54dcbe71ed784a0daf11390401a555ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    209 schema:name Guidelines as Topic
    210 rdf:type schema:DefinedTerm
    211 N62199429b1f746ceb64f863902e2b80e schema:name Springer Nature - SN SciGraph project
    212 rdf:type schema:Organization
    213 N629e992e50b847a099174abb172910f8 schema:name pubmed_id
    214 schema:value 30925922
    215 rdf:type schema:PropertyValue
    216 N6afc4e0587da45bd93dc80ba46d352f1 rdf:first sg:person.01110354341.05
    217 rdf:rest Nf2e608d3f7b740339594f7619f38d43a
    218 N7da6ff61c50742898f653c4191030406 schema:volumeNumber 23
    219 rdf:type schema:PublicationVolume
    220 N8099d3a3a16f4da790d3e65f278ccaf8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    221 schema:name Intensive Care Units
    222 rdf:type schema:DefinedTerm
    223 N8c715525617f4215910d124d4b7f0723 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    224 schema:name Glomerular Filtration Rate
    225 rdf:type schema:DefinedTerm
    226 N8c920f83968445f1a744494abd18811f schema:issueNumber 1
    227 rdf:type schema:PublicationIssue
    228 N8f138b2e3ba6448ca0e8aa1d0749078a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    229 schema:name Societies, Medical
    230 rdf:type schema:DefinedTerm
    231 N95f3ac8a0a9149afa250444f3e31d284 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    232 schema:name Drug Monitoring
    233 rdf:type schema:DefinedTerm
    234 Na1813939014748c2b4a744e78abcba14 rdf:first sg:person.01203524231.40
    235 rdf:rest Nb01c527797b24d3598545e28ab5fdab3
    236 Nb01c527797b24d3598545e28ab5fdab3 rdf:first sg:person.01352406745.54
    237 rdf:rest N21ab78da2e84461ca1fd1cd86aad44d7
    238 Nb09483f4c14e47439030cb571c28f328 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    239 schema:name Serum Albumin
    240 rdf:type schema:DefinedTerm
    241 Nb191c15c5cbc4a8592a5abcd504d40f8 rdf:first sg:person.0664453716.41
    242 rdf:rest N54c4b8508b3d4c21875a644771164e90
    243 Nb413b5e6e8ae41e58748a5a137a66046 rdf:first sg:person.01311772632.70
    244 rdf:rest N4e777c2fe96b48dda6ab11d0a93cdb1d
    245 Nb8a4331bea3542ec8b29f7c1044ae46a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    246 schema:name Anti-Bacterial Agents
    247 rdf:type schema:DefinedTerm
    248 Nccf0cdd1cb3649d4be42e34e79d902c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    249 schema:name Humans
    250 rdf:type schema:DefinedTerm
    251 Nedf92b1e35024b32850ea81a1bb7a915 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    252 schema:name beta-Lactamases
    253 rdf:type schema:DefinedTerm
    254 Nf2e608d3f7b740339594f7619f38d43a rdf:first sg:person.07443737243.21
    255 rdf:rest rdf:nil
    256 Nf33967c5ae904eaca4b58e72a982b97b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    257 schema:name France
    258 rdf:type schema:DefinedTerm
    259 Nf9c0ce98a75b4194804bac1afb8b3edc rdf:first sg:person.01205666273.30
    260 rdf:rest N15adfb29a0934c0ebf4d6e49104b6e4f
    261 Nfc1a29b69d1544f2993ebf6f4bb66315 schema:name dimensions_id
    262 schema:value pub.1113107158
    263 rdf:type schema:PropertyValue
    264 Nfc9b81b0fe5b49259d7b7bb3cf643b66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    265 schema:name Societies, Pharmaceutical
    266 rdf:type schema:DefinedTerm
    267 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    268 schema:name Medical and Health Sciences
    269 rdf:type schema:DefinedTerm
    270 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    271 schema:name Clinical Sciences
    272 rdf:type schema:DefinedTerm
    273 sg:journal.1117766 schema:issn 1364-8535
    274 1466-609X
    275 schema:name Critical Care
    276 schema:publisher Springer Nature
    277 rdf:type schema:Periodical
    278 sg:person.01032325745.23 schema:affiliation grid-institutes:None
    279 schema:familyName Benaboud
    280 schema:givenName Sihem
    281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032325745.23
    282 rdf:type schema:Person
    283 sg:person.01065077071.65 schema:affiliation grid-institutes:grid.277151.7
    284 schema:familyName Dailly
    285 schema:givenName Eric
    286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065077071.65
    287 rdf:type schema:Person
    288 sg:person.01110354341.05 schema:affiliation grid-institutes:grid.414271.5
    289 schema:familyName Lemaitre
    290 schema:givenName Florian
    291 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110354341.05
    292 rdf:type schema:Person
    293 sg:person.01111665536.58 schema:affiliation grid-institutes:grid.413852.9
    294 schema:familyName Goutelle
    295 schema:givenName Sylvain
    296 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111665536.58
    297 rdf:type schema:Person
    298 sg:person.01203524231.40 schema:affiliation grid-institutes:grid.413858.3
    299 schema:familyName Bennis
    300 schema:givenName Youssef
    301 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203524231.40
    302 rdf:type schema:Person
    303 sg:person.01205666273.30 schema:affiliation grid-institutes:None
    304 schema:familyName Guilhaumou
    305 schema:givenName Romain
    306 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01205666273.30
    307 rdf:type schema:Person
    308 sg:person.01216312122.58 schema:affiliation grid-institutes:None
    309 schema:familyName Mongardon
    310 schema:givenName Nicolas
    311 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01216312122.58
    312 rdf:type schema:Person
    313 sg:person.01302555643.53 schema:affiliation grid-institutes:grid.410527.5
    314 schema:familyName Scala-Bertola
    315 schema:givenName Julien
    316 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302555643.53
    317 rdf:type schema:Person
    318 sg:person.01311772632.70 schema:affiliation grid-institutes:grid.411175.7
    319 schema:familyName Gandia
    320 schema:givenName Peggy
    321 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01311772632.70
    322 rdf:type schema:Person
    323 sg:person.01352406745.54 schema:affiliation grid-institutes:grid.411162.1
    324 schema:familyName Dahyot-Fizelier
    325 schema:givenName Claire
    326 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352406745.54
    327 rdf:type schema:Person
    328 sg:person.0604417143.54 schema:affiliation grid-institutes:grid.411165.6
    329 schema:familyName Roger
    330 schema:givenName Claire
    331 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0604417143.54
    332 rdf:type schema:Person
    333 sg:person.0664453716.41 schema:affiliation grid-institutes:None
    334 schema:familyName Lefeuvre
    335 schema:givenName Sandrine
    336 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664453716.41
    337 rdf:type schema:Person
    338 sg:person.07443737243.21 schema:affiliation grid-institutes:grid.50550.35
    339 schema:familyName Garnier
    340 schema:givenName Marc
    341 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07443737243.21
    342 rdf:type schema:Person
    343 sg:pub.10.1007/bf01712162 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038871033
    344 https://doi.org/10.1007/bf01712162
    345 rdf:type schema:CreativeWork
    346 sg:pub.10.1007/s00134-013-3187-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016715841
    347 https://doi.org/10.1007/s00134-013-3187-2
    348 rdf:type schema:CreativeWork
    349 sg:pub.10.1007/s00134-015-4188-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029454839
    350 https://doi.org/10.1007/s00134-015-4188-0
    351 rdf:type schema:CreativeWork
    352 sg:pub.10.1007/s10096-016-2832-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029650859
    353 https://doi.org/10.1007/s10096-016-2832-4
    354 rdf:type schema:CreativeWork
    355 sg:pub.10.1007/s11096-016-0334-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020337346
    356 https://doi.org/10.1007/s11096-016-0334-1
    357 rdf:type schema:CreativeWork
    358 sg:pub.10.1007/s13318-017-0439-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092187076
    359 https://doi.org/10.1007/s13318-017-0439-5
    360 rdf:type schema:CreativeWork
    361 sg:pub.10.1007/s40005-013-0073-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047074920
    362 https://doi.org/10.1007/s40005-013-0073-4
    363 rdf:type schema:CreativeWork
    364 sg:pub.10.1007/s40262-012-0018-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026024203
    365 https://doi.org/10.1007/s40262-012-0018-5
    366 rdf:type schema:CreativeWork
    367 sg:pub.10.1007/s40264-017-0578-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090909191
    368 https://doi.org/10.1007/s40264-017-0578-2
    369 rdf:type schema:CreativeWork
    370 sg:pub.10.1067/mcp.2002.121829 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044113659
    371 https://doi.org/10.1067/mcp.2002.121829
    372 rdf:type schema:CreativeWork
    373 sg:pub.10.1186/1471-2334-11-181 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017207082
    374 https://doi.org/10.1186/1471-2334-11-181
    375 rdf:type schema:CreativeWork
    376 sg:pub.10.1186/2110-5820-2-35 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020507376
    377 https://doi.org/10.1186/2110-5820-2-35
    378 rdf:type schema:CreativeWork
    379 sg:pub.10.1186/cc10257 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005923181
    380 https://doi.org/10.1186/cc10257
    381 rdf:type schema:CreativeWork
    382 sg:pub.10.1186/cc10441 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037453353
    383 https://doi.org/10.1186/cc10441
    384 rdf:type schema:CreativeWork
    385 sg:pub.10.1186/cc11862 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017822371
    386 https://doi.org/10.1186/cc11862
    387 rdf:type schema:CreativeWork
    388 sg:pub.10.1186/cc12544 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041305613
    389 https://doi.org/10.1186/cc12544
    390 rdf:type schema:CreativeWork
    391 sg:pub.10.1186/cc13094 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023558979
    392 https://doi.org/10.1186/cc13094
    393 rdf:type schema:CreativeWork
    394 sg:pub.10.1186/cc8941 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040862782
    395 https://doi.org/10.1186/cc8941
    396 rdf:type schema:CreativeWork
    397 sg:pub.10.1186/cc9091 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031159164
    398 https://doi.org/10.1186/cc9091
    399 rdf:type schema:CreativeWork
    400 sg:pub.10.1186/s13054-016-1255-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1012708353
    401 https://doi.org/10.1186/s13054-016-1255-z
    402 rdf:type schema:CreativeWork
    403 sg:pub.10.1186/s13054-017-1856-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092690158
    404 https://doi.org/10.1186/s13054-017-1856-1
    405 rdf:type schema:CreativeWork
    406 sg:pub.10.1186/s13054-018-2155-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107133834
    407 https://doi.org/10.1186/s13054-018-2155-1
    408 rdf:type schema:CreativeWork
    409 sg:pub.10.1186/s13613-015-0093-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026015877
    410 https://doi.org/10.1186/s13613-015-0093-5
    411 rdf:type schema:CreativeWork
    412 sg:pub.10.2165/00003088-200039050-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033874588
    413 https://doi.org/10.2165/00003088-200039050-00003
    414 rdf:type schema:CreativeWork
    415 sg:pub.10.2165/00003088-200847030-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033831230
    416 https://doi.org/10.2165/00003088-200847030-00003
    417 rdf:type schema:CreativeWork
    418 sg:pub.10.2165/11318140-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039277611
    419 https://doi.org/10.2165/11318140-000000000-00000
    420 rdf:type schema:CreativeWork
    421 sg:pub.10.2165/11319370-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045903643
    422 https://doi.org/10.2165/11319370-000000000-00000
    423 rdf:type schema:CreativeWork
    424 sg:pub.10.2165/11539220-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045065825
    425 https://doi.org/10.2165/11539220-000000000-00000
    426 rdf:type schema:CreativeWork
    427 grid-institutes:None schema:alternateName AP-HM Hôpital de la Timone, Service de Pharmacologie Clinique et Pharmacovigilance, 264 rue Saint Pierre, 13005, Marseille, France
    428 AP-HP Hôpital Cochin, Service de Pharmacologie, 27 rue du Faubourg St-Jacques, 75679, Paris Cedex 14, France
    429 AP-HP Hôpital Henri Mondor, Département d’Anesthésie-Réanimation, 51 Avenue du Maréchal de Lattre de Tassigny, 94000, Créteil, France
    430 CHR d’Orléans, Laboratoire de Biochimie, 14 Avenue de l’Hôpital, 45067, Orléans, France
    431 schema:name AP-HM Hôpital de la Timone, Service de Pharmacologie Clinique et Pharmacovigilance, 264 rue Saint Pierre, 13005, Marseille, France
    432 AP-HP Hôpital Cochin, Service de Pharmacologie, 27 rue du Faubourg St-Jacques, 75679, Paris Cedex 14, France
    433 AP-HP Hôpital Henri Mondor, Département d’Anesthésie-Réanimation, 51 Avenue du Maréchal de Lattre de Tassigny, 94000, Créteil, France
    434 CHR d’Orléans, Laboratoire de Biochimie, 14 Avenue de l’Hôpital, 45067, Orléans, France
    435 rdf:type schema:Organization
    436 grid-institutes:grid.277151.7 schema:alternateName CHU de Nantes, Département de Pharmacologie Clinique, 5 allée de l’île gloriette, 44093, Nantes Cedex 01, France
    437 schema:name CHU de Nantes, Département de Pharmacologie Clinique, 5 allée de l’île gloriette, 44093, Nantes Cedex 01, France
    438 rdf:type schema:Organization
    439 grid-institutes:grid.410527.5 schema:alternateName CHRU de Nancy, Département de pharmacologie clinique et de toxicologie, 29 rue Lionnois, 54000, Nancy, France
    440 schema:name CHRU de Nancy, Département de pharmacologie clinique et de toxicologie, 29 rue Lionnois, 54000, Nancy, France
    441 rdf:type schema:Organization
    442 grid-institutes:grid.411162.1 schema:alternateName CHU de Poitiers, Département d’Anesthésie Réanimation, 2 Rue de la Milétrie, 86021, Poitiers, France
    443 schema:name CHU de Poitiers, Département d’Anesthésie Réanimation, 2 Rue de la Milétrie, 86021, Poitiers, France
    444 rdf:type schema:Organization
    445 grid-institutes:grid.411165.6 schema:alternateName CHU de Nîmes, Département d’anesthésie, réanimation, douleur et médicine d’urgence, Place du Pr Robert Debré, 30029, Nîmes cedex 9, France
    446 schema:name CHU de Nîmes, Département d’anesthésie, réanimation, douleur et médicine d’urgence, Place du Pr Robert Debré, 30029, Nîmes cedex 9, France
    447 rdf:type schema:Organization
    448 grid-institutes:grid.411175.7 schema:alternateName CHU de Toulouse, Laboratoire de Pharmacocinétique et Toxicologie Clinique, Institut Fédératif de Biologie, 330, avenue de Grande-Bretagne, 31059, Toulouse cedex 9, France
    449 schema:name CHU de Toulouse, Laboratoire de Pharmacocinétique et Toxicologie Clinique, Institut Fédératif de Biologie, 330, avenue de Grande-Bretagne, 31059, Toulouse cedex 9, France
    450 rdf:type schema:Organization
    451 grid-institutes:grid.413852.9 schema:alternateName CHU de Lyon, Service de Pharmacie, Groupement Hospitalier Nord, Hôpital Pierre Garraud, 136 rue du Commandant Charcot, 69322, Lyon cedex 05, France
    452 schema:name CHU de Lyon, Service de Pharmacie, Groupement Hospitalier Nord, Hôpital Pierre Garraud, 136 rue du Commandant Charcot, 69322, Lyon cedex 05, France
    453 rdf:type schema:Organization
    454 grid-institutes:grid.413858.3 schema:alternateName CHU d’Amiens Picardie, Service de Pharmacologie Clinique, UPJV EA7517, Avenue Laennec, 80054, Amiens Cedex 1, France
    455 schema:name CHU d’Amiens Picardie, Service de Pharmacologie Clinique, UPJV EA7517, Avenue Laennec, 80054, Amiens Cedex 1, France
    456 rdf:type schema:Organization
    457 grid-institutes:grid.414271.5 schema:alternateName CHU Pontchaillou, Service de Pharmacologie Clinique et épidémiologique, 2 Rue Henri le Guilloux, 35000, Rennes, France
    458 schema:name CHU Pontchaillou, Service de Pharmacologie Clinique et épidémiologique, 2 Rue Henri le Guilloux, 35000, Rennes, France
    459 rdf:type schema:Organization
    460 grid-institutes:grid.50550.35 schema:alternateName AP-HP Hôpital Tenon, Département d’Anesthésie et Réanimation, 4 rue de la Chine, 75020, Paris, France
    461 schema:name AP-HP Hôpital Tenon, Département d’Anesthésie et Réanimation, 4 rue de la Chine, 75020, Paris, France
    462 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...